Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts.
Journal of cancer research and clinical oncology 2008 Feb 9; In press
Oliveira J C, Souza K K, Dias M M, Faria M C, Ropelle E R, Flores M B S, Ueno M M, Velloso L A, Saad S T, Saad M J A, Carvalheira J B C
Departament of Internal Medicine, FCM-UNICAMP, Cidade Universitária Zeferino Vaz, Campinas, SP, 13081-970, Brazil.
Proper activation of phosphoinositide 3-kinase-Akt pathway is critical for the prevention of tumorigenesis. Recent data have characterized a negative feedback loop, wherein mammalian target of rapamycin (mTOR) blocks additional activation of the Akt/mTOR pathway through inhibition insulin receptor substrate 1 (IRS-1) function. However, the potential of IRS-1 inhibition during rapamycin treatment has not been examined. Herein, we show that IRS-1 antisense oligonucleotide and rapamycin synergistically antagonize the activation of mTOR in vivo and induced tumor suppression, through inhibition of proliferation and induction of apoptosis, in prostate cancer cell xenografts. These data demonstrate that the addition of agents that blocks IRS-1 potentiate the effect of mTOR inhibition in the growth of prostate cancer cell xenografts.
Keywords: prostate cancer rapamycin IRS-1